Search results

  1. hotblack

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    It wasn’t the direct contact route I was most interested in but the other two routes mentioned in the paper, release and capture through EVs or even free mitochondria. As I think I mentioned in another thread I’m very much in throwing stuff at the wall and seeing what sticks territory, with...
  2. hotblack

    How do you use AI for medical feedback?

    For the sort of usage described here no and I absolutely wouldn’t. It’s understandable to want to try everything and anything but I’d really caution against this sort of use. We’ve seen how LLM chatbots can lead people, particularly those who are vulnerable or desperate, down iffy paths. It’s a...
  3. hotblack

    New podcast on medical innovation - Hard Drugs

    There’s been a couple more episodes of this which are well worth a listen 100 years of insulin in 15 minutes is really interesting and short Hacking proteins with AI is longer but with other threads talking about AI seems particularly relevant. Along with an article from last year How Neil...
  4. hotblack

    Will AI programs/models significantly aid in producing viable treatments for ME/CFS?

    I found this difficult to answer because of the significantly qualifier and different people’s understanding… But in short, they already are, just not in the way public discussion often goes. DecodeMe used AI/ML. Other papers on here use AI/ML and AI/ML is being used in labs for things like...
  5. hotblack

    Preprint Identification and Validation of Novel Combinatorial Genetic Risk Factors for Endometriosis across Multiple UK and US Patient Cohorts, 2025, Sardell+

    It looks like the Results has been changed too with this detail added And they’ve changed some gene findings and categorisation too, from this To this With this they’ve gone from 77 novel gene associations found to 75.
  6. hotblack

    Preprint Identification and Validation of Novel Combinatorial Genetic Risk Factors for Endometriosis across Multiple UK and US Patient Cohorts, 2025, Sardell+

    What’s changed, they say From a visual inspection it looks as if the Discussion section is where the main changes are. There’s a new subsection “First Genetic Evidence in Endometriosis for Many Genes “ and an extra paragraph n “Novel Drug Discovery and Repurposing Targets” Although there...
  7. hotblack

    Deep Sequencing of BCR Heavy Chain Repertoires in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, 2025, Ryback et al

    I remember that 2019/20 winter before covid they were collecting but obviously stopped, as I had been scheduled to give more blood. I’m not sure exactly when they restarted but Caroline was doing limited home visits later in 2021 IIRC. The Ryback paper mentions it uses the same samples as...
  8. hotblack

    How would an Average pwME/carer (no biology knowledge or access to S4ME) be able to tell when a mechanism has been discovered vs bio “memes” and hype?

    Probably not if it doesn’t directly impact them. It’s just vaguely interesting stuff that washes over you. Most of us are probably only pretty superficially interested in things until it means something to us tbf.
  9. hotblack

    Updates from the UK ME/CFS Biobank / CureME team

    I can’t see this on the CureME website or social media but ME Research have posted that those set to receive the free samples from the Biobank have been announced. Hopefully we’lo get more details soon.
  10. hotblack

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    Thanks for the update, it all sounds very interesting. I’m sure we’re all joining you in crossing things regarding funding. Maybe Twoflower will turn up with some gold!
  11. hotblack

    Diagnosis, Prognosis, and Drug Target Discovery for Chronic Widespread Pain: A Large Proteogenomic Study, 2025, Chen et al

    Looked like an interesting paper on data driven drug discovery for chronic pain using a proteome-wide association study (PWAS) and things like gene ontology enrichment analysis on UK Biobank data (protein and genetic data). They used machine learning with a proteomic-based score and clinical...
  12. hotblack

    Diagnosis, Prognosis, and Drug Target Discovery for Chronic Widespread Pain: A Large Proteogenomic Study, 2025, Chen et al

    Diagnosis, Prognosis, and Drug Target Discovery for Chronic Widespread Pain: A Large Proteogenomic Study Li Chen, Eoin Kelleher, Ruogu Meng, Duanke Liu, Yuchen Guo, Yunhe Wang, Yaqing Gao, Zhe Huang, Zhu Liang, Shuai Yuan, Chao Zeng, Jun Ma, Yanhui Dong, Anushka Irani, Guanghua Lei, Junqing...
  13. hotblack

    How would an Average pwME/carer (no biology knowledge or access to S4ME) be able to tell when a mechanism has been discovered vs bio “memes” and hype?

    Excellent question @Yann04 and zi share the feelings about the value of S4ME. And excellent summary from @Hutan which I think describes a lot of my journey through going along with things to accepting the reality I knew earlier than those around me. How will people know when the real deal...
  14. hotblack

    Review Mechanisms of resistance to daratumumab in patients with multiple myeloma, 2024, Iversen

    I hope it’s all or mostly correct! Yes, it can do things without killing cells, like the calcium, signalling and metabolic transfer changes I mentioned (see the wikipedia page for more info). But I don’t know about ME/CFS. It’s probably unlikely these other effects would be the sole route of...
  15. hotblack

    Review Mechanisms of resistance to daratumumab in patients with multiple myeloma, 2024, Iversen

    Yeah, it’s covered in the paper, but I’ll try to expand on this a bit. Daratumumab is a CD38 antibody, so binds to CD38. CD38 is found on many immune cells but is particularly highly expressed on multiple myeloma cells. When it binds to them it can have various effects including - tagging that...
  16. hotblack

    Review Mechanisms of resistance to daratumumab in patients with multiple myeloma, 2024, Iversen

    Yeah, there’s bound to be some differences in context. But if daratumumab ends up being the real deal and we can leverage all that work and research to help efficacy for ME/CFS that would be great. Understanding the complete mechanism involved would help.
  17. hotblack

    Review Mechanisms of resistance to daratumumab in patients with multiple myeloma, 2024, Iversen

    Really interesting, thanks @ryanc97 Link to the full paper From a quick scan… a few bits that stood out to me And that daratumumab itself changes that makeup In closing they say This seems to indicate the characteristics or quality of the NK cells as much as the quantity is important...
  18. hotblack

    Trial Report Feasibility and tolerability of dual-target [rTMS] for treatment of [ME/CFS]: An open label pilot study, 2025, Corlier et al

    Interesting to see that Solve ME/CFS were involved. I wonder how much input they had on the design? An organisation which exists to promote TMS was also involved in funding the article (but not the research it seems). This from the Acknowledgments
  19. hotblack

    Review The power and potential of mitochondria transfer, 2023, Borcherding et al

    Deciding what should be degraded in the cell or ejected from the cell is one area I thought about. And some cells deliberately chuck things out for other cells to take care of for them I believe. But cells which normally take care of their own rubbish may decide not to or have their own internal...
Back
Top Bottom